New German Trial Shows Tricuspid Valve Repair Cuts Death and Heart Failure Hospitalization, Not Just Quality of Life

For years, doctors had a valve procedure that made heart patients feel better but couldn't prove it kept them alive longer or out of the hospital. On August 30, 2026, Jörg Hausleiter, MD, of Ludwig-Maximilians-Universität München, presented the TRIC-I-HF trial results at the European Society of Cardiology Congress in Munich, with simultaneous publication in the New England Journal of Medicine.

The trial tested transcatheter tricuspid valve repair, a catheter-based fix for a leaky tricuspid valve, against medical therapy alone in patients with severe tricuspid regurgitation at high risk for future heart failure events. Tricuspid regurgitation causes the right side of the heart to enlarge and drives fatigue, shortness of breath, and fluid overload. Drug options for it are limited, according to the European Society of Cardiology.

The Numbers

The trial enrolled 360 patients across 29 high-volume heart valve centers in Germany, splitting them 237 to repair-plus-medical-therapy and 123 to medical therapy alone. Average age was 80.3, and 56.4% were women, according to the European Society of Cardiology.

At one year, the win ratio for a combined measure of death, heart failure hospitalization, and quality-of-life failure was 2.42 in favor of the valve repair, with a 95% confidence interval of 1.76 to 3.33. At three years, 52.4% of the repair group was free of death or heart failure hospitalization, compared to 21.0% on medical therapy alone, a hazard ratio of 0.40, according to results reported by both the European Society of Cardiology and tctmd.

Hausleiter told the Hot Line session that translates to a 60% relative reduction in the combined endpoint of mortality and heart failure hospitalization, with a p-value of 0.0001. The number needed to treat to prevent one death or hospitalization at one year was four patients, according to tctmd and MedPage Today.

Why This One Worked When Others Didn't

Two prior randomized trials, Tri.Fr and TRILUMINATE Pivotal, showed the same procedure improved quality of life but failed to move the needle on hospitalization or death, according to tctmd. TRIC-I-HF investigators say they deliberately enrolled sicker patients, defining high risk as a heart failure hospitalization in the prior year or evidence of cardiorenal or cardiohepatic syndrome, per the European Society of Cardiology.

Mohamad Alkhouli, MD, of Mayo Clinic, who wasn't involved in the trial, called it the one interventionalists have been waiting for. "It's the first one that shows hard clinical outcome change with tricuspid valve interventions. It feels like a COAPT-like moment for the field," he told tctmd, referencing the 2018 trial that established transcatheter mitral valve repair could cut heart failure rehospitalizations and mortality.

Rebecca Hahn, MD, of Columbia University Medical Center, the trial's discussant at ESC, called the result "just an incredible result" and said it will "inform patients and clinicians about the benefit of transcatheter repair therapy," according to MedPage Today.

The Caveats Nobody Should Skip

All 29 participating sites were high-volume heart valve centers, and 98% of intervention patients received a technique called tricuspid transcatheter edge-to-edge repair, according to the European Society of Cardiology. That matters because MedPage Today notes the procedure "remains a technically demanding procedure with a pronounced volume-outcome relationship," meaning results from expert German centers may not translate directly to lower-volume hospitals elsewhere.

A reasonable skeptic could point out that two prior randomized trials of the same basic procedure failed to show these hard outcomes, and this is a single trial from one country's specialist network. Hahn herself said she's "eagerly looking forward to subgroup analyses that may further inform clinicians about who, when, and how to treat," indicating the field isn't considering this settled science yet.

Hausleiter also flagged the real-world tradeoff for these patients directly. "For most of the patients, the quality-of-life improvement matters more than an increased lifespan because they are usually already around 80 years of age," he said at a press conference, according to Healio. He added the hard-outcome data "will also have a significant impact on healthcare costs" by potentially cutting hospitalizations, though the trial didn't report a cost analysis.

Two More Trials, Same Congress

Two other late-breaking trials at the same ESC session addressed different corners of structural heart disease. The TAVI PCI trial, also published in NEJM, found that doing TAVI (a catheter-based aortic valve replacement) before coronary stenting was noninferior to doing stenting first in patients with both aortic stenosis and coronary artery disease, with primary endpoint events in 22.2% of the TAVI-first group versus 24.2% of the PCI-first group, according to the American College of Cardiology. The trial's presenter noted fewer TAVI-first patients ultimately needed PCI at all once the valve was fixed.

The ACASA-TAVI trial, published in JAMA, tested blood-thinning strategies after TAVI in 360 patients and found a once-daily blood thinner reduced leaflet thickening on imaging compared to aspirin, with life-threatening bleeding occurring only in the aspirin group, according to Øyvind Lie, MD, PhD, of Oslo University Hospital.

None of the three trials has yet changed formal treatment guidelines. The next test for TRIC-I-HF will be whether cardiology societies incorporate the results into practice recommendations, and whether the outcomes hold up outside Germany's 29 specialist centers as more hospitals adopt the procedure.